Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
USRE41884E1 · kind E1 · reissue
24Cited by
13References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 6, 2008 |
| Grant date | Oct 26, 2010 |
| Priority date | — |
| Expiry date | Feb 6, 2028 |
Classification
- Technology area (CPC —)General
Abstract
Disclosed are methods of intravenous administration of nanoparticulate drug formulations to a mammal to avoid adverse hemodynamic effects: by reducing the rate and concentration of the nanoparticles in the formulations; or by pre-treating the subject with histamine; or by pretreating the subject with a desensitizing amount of the nanoparticulate drug formulations.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.